Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CDNA |
---|
US Equity | 79.9% |
---|---|
Int'l Equity | 19.7% |
Cash | 0.4% |
CDN Equity | 0 |
Fixed Income | 0 |
Other | 0 |
Healthcare | 99.6% |
---|---|
Basic Mat. | 0 |
Communication Services | 0 |
Consumer Cyclical | 0 |
Consumer Defensive | 0 |
Energy | 0 |
Financial Serv.s | 0 |
Industrials | 0 |
Real Estate | 0 |
Technology | 0 |
Utilities | 0 |
United States | 80.2% |
---|---|
Europe | 3.9% |
Asia/Oceania | 1.8% |
Africa | 0 |
Latin America | 0 |
Canada | 0 |
Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
---|---|---|---|---|
Illumina Inc | Long | 3.4% | -0.74% | $173.9K |
Beam Therapeutics Inc | Long | 3.2% | -0.69% | $168.0K |
Lonza Group Ltd | Long | 3.2% | -0.48% | $168.0K |
Moderna Inc | Long | 3.2% | -0.69% | $165.4K |
CRISPR Therapeutics AG | Long | 3.0% | -0.70% | $157.6K |
Thermo Fisher Scientific Inc | Long | 3.0% | -0.50% | $157.3K |
Twist Bioscience Corp | Long | 3.0% | -0.68% | $155.0K |
Vertex Pharmaceuticals Inc | Long | 2.9% | -0.74% | $151.6K |
AbbVie Inc | Long | 2.9% | -0.66% | $149.3K |
Sarepta Therapeutics Inc | Long | 2.8% | -0.72% | $145.8K |
Time Horizon | Star Rating |
---|---|
Overall Rating | Not Rated |
3 Year Rating | Not Rated |
5 Year Rating | Not Rated |
10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | --- |
---|---|
Category | Sector Equity |
Sponsor | CI Global Asset Management |
Inception | February 24, 2022 |
CDNA seeks to replicate, to the extent reasonably possible, the performance of a global biotechnology and genomics industry index, net of expenses. Currently, CDNA seeks to replicate the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR (the “Indexâ€). The Index intends to track the performance of companies that have business operations in the global biotechnology and genomics industry using the ARTIS® classification system. The Index hedges foreign currency exposure back to Canadian dollars.
Total Net Assets | $5.2M |
---|---|
Shares Out. | 300.0K |
Net Asset Value (NAV) | $15.45 |
Prem/Discount to NAV | -2.15% |
P/E Ratio | --- |
Dividend Yield | 0.58% |
Dividend per Share | 0.09 CAD |
Ex-Dividend Date | 03/21/2024 |
Dividend Payment Date | 03/28/2024 |
Beta | --- |
Morningstar Investment Style | Sector Equity |
Equity Style | Mid Cap Growth |
Credit Quality / Duration | --- |
Actual Management Fee | 0.40% |
---|---|
Actual Mgmt. Expense Ratio (MER) | 0.44% |